RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
Public ClinicalTrials.gov record NCT02867761. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study hypothesis is that symptomatic current and former smokers with spirometric values within the normal range (post-bronchodilator FEV1/FVC≥0.70 and post-BD FVC ≥ 70% predicted will still derive symptomatic benefit from long-acting bronchodilator therapy even though they are excluded from current GOLD guideline recommendations.
Study identification
- NCT ID
- NCT02867761
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 780 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 29, 2017 (Actual)
- Primary completion
- Jul 7, 2021 (Actual)
- Completion
- Jul 7, 2021 (Actual)
- Last update posted
- Apr 13, 2023
2017 – 2021
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Universityof Alabama | Birmingham | Alabama | 35294 | — |
| University of California | Los Angeles | California | 90095 | — |
| University of California | San Francisco | California | 94143 | — |
| LABIOMED at Harbor-UCLA Medical Center | Torrance | California | 90502 | — |
| University of Illinois | Chicago | Illinois | 60608 | — |
| Northwestern University | Chicago | Illinois | 60657 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Johns Hopkins University | Baltimore | Maryland | 21224 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Minneapolis VA Medical Center | Minneapolis | Minnesota | 55417 | — |
| Minnesota Health partners | Saint Paul | Minnesota | 55130 | — |
| Cornell University | New York | New York | 10021 | — |
| Duke University | Durham | North Carolina | 27705 | — |
| Temple University | Philadelphia | Pennsylvania | 19140 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02867761, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2023 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02867761 live on ClinicalTrials.gov.